Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of £11.33 per Ordinary share.
Material Changes
The document details an increase in shareholdings for specific individuals following the re-investment of the dividend paid to shareholders on July 8, 2010. The specific increases are:
- Mr A P Witty: 822 shares
- Mrs C M Witty: 735 shares
- Mr J S Heslop: 572 shares
- Mr D Learmouth: 319 shares
- Dr D Pulman: 345 shares
- Mrs C R Pulman: 70 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory notification of share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the dividend reinvestment date of July 8, 2010, and the corresponding share price of £11.33.
- Confirm the updated total shareholdings for the named directors and connected persons.
- Note that this filing does not contain operational or financial performance data for the period.